[HTML] frontiersin.org

[HTML][HTML] Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab

L Zhang, X Wen, Y Hou, Y Yang, W Song… - Frontiers in …, 2022 - frontiersin.org
Background Atopic dermatitis (AD) is one of the most common chronic inflammatory skin
diseases. Dupilumab, a monoclonal antibody that targets the interleukin (IL)-4 and IL-13 …
被引用次数：13 相关文章

Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab

L Zhang, X Wen, Y Hou, Y Yang… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Atopic dermatitis (AD) is one of the most common chronic inflammatory skin
diseases. Dupilumab, a monoclonal antibody that targets the interleukin (IL)-4 and IL-13 …
[HTML] nih.gov

[HTML][HTML] Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab

L Zhang, X Wen, Y Hou, Y Yang, W Song… - Frontiers in …, 2022 - ncbi.nlm.nih.gov
Background Atopic dermatitis (AD) is one of the most common chronic inflammatory skin
diseases. Dupilumab, a monoclonal antibody that targets the interleukin (IL)-4 and IL-13 …

Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab

L Zhang, X Wen, Y Hou, Y Yang, W Song… - Frontiers in …, 2022 - europepmc.org
Background Atopic dermatitis (AD) is one of the most common chronic inflammatory skin
diseases. Dupilumab, a monoclonal antibody that targets the interleukin (IL)-4 and IL-13 …

Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab.

L Zhang, X Wen, Y Hou, Y Yang, W Song… - Frontiers in …, 2022 - europepmc.org
Background Atopic dermatitis (AD) is one of the most common chronic inflammatory skin
diseases. Dupilumab, a monoclonal antibody that targets the interleukin (IL)-4 and IL-13 …